Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC)

NCT03742986 is registered in ClinicalTrials.gov with NYU Langone Health as lead sponsor.

NCT NCT03742986
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03742986 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC)
Lead sponsor
NYU Langone Health
Phase
Phase 2
Overall status
Completed
Start date
May 2, 2019
Completion date
June 12, 2023
Enrollment
8 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer